NORAD and breast cancer: We observed a reduction in doxorubicin IC50 upon NORAD KD through alamarBlue cellular viability assay (Figures 2D and S5, IC50 shifted from 0.3779 to 0.05680 μM), indicating that NORAD KD sensitizes breast cancer cells to chemotherapy.